1. Non small cell lung cancer patients confirmed by pathology;

2. They were 18-80 years old;

3. The tumor could not be resected or could not tolerate surgery;

4. Planed to receive chemoradiotherapy and subsequent immunoconsolidation therapy;

5. Clinical stage III (AJCC, 8th Edition, 2017);

6. After systematic detection of non-small cell lung cancer core indicators including EGFR, ALK, ros1, KRAS, ntrk, TMB, etc;

7. Patient informed consent.

Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy